Indicaciones para el uso de heparinas de bajo peso molecular en pacientes con diabetes mellitus

Kannel, 1979, Diabetes and cardiovascular risk factors: the Framingham study, Circulation., 59, 8, 10.1161/01.CIR.59.1.8 Medrano, 2007 Tsai, 2002, Cardiovascular risk factors and venous thromboembolism incidence, Arch Intern Med., 162, 1182, 10.1001/archinte.162.10.1182 Goldhaber, 1997, A prospective study of risk factors for pulmonary embolism in women, JAMA., 277, 642, 10.1001/jama.1997.03540320044033 Petrauskiene, 2005, The risk of venous thromboembolism is markedly elevated in patients with diabetes, Diabetologia., 48, 1017, 10.1007/s00125-005-1715-5 Geerts, 2008, Prevention of venous thromboembolism: American College of Chest Physician Evidence-Based Clinical Practice Guidelines (8th edition), Chest., 133, 381S, 10.1378/chest.08-0656 Franchini, 2008, Venous and arterial thrombosis: different sides of the same coin?, Eur J Intern Med., 19, 476, 10.1016/j.ejim.2007.10.019 Lim, 2009, Using low molecular weight heparin in special populations, J Thromb Thrombolysis Douketis, 2008, Prophylaxis against deep venous thrombosis in critically ill patients with severe renal insufficiency with low molecular with heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study, Arch Intern Med., 1688, 1805, 10.1001/archinte.168.16.1805 Kalani, 2007, Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers, Thromb Res., 120, 653, 10.1016/j.thromres.2006.12.006 Rullan, 2008, Treatment of chronic diabetic foot ulcers with bemiparin: a randomized, triple-blind, placebo-controlled, clinical trial, Diabet Med., 25, 1090, 10.1111/j.1464-5491.2008.02527.x